A5050437850- Schizophrenia research and treatment
- Psoriasis: Treatment and Pathogenesis
- Healthcare Decision-Making and Restraints
- Bipolar Disorder and Treatment
- Spondyloarthritis Studies and Treatments
- Eosinophilic Esophagitis
- Family Caregiving in Mental Illness
- Inflammatory Bowel Disease
- Autoimmune and Inflammatory Disorders Research
- Healthcare cost, quality, practices
- Mental Health and Psychiatry
- Cardiac, Anesthesia and Surgical Outcomes
- Rheumatoid Arthritis Research and Therapies
- Pelvic and Acetabular Injuries
- Biosimilars and Bioanalytical Methods
- Abdominal Trauma and Injuries
- Family and Disability Support Research
- Iron Metabolism and Disorders
- Multiple Sclerosis Research Studies
- Pharmaceutical studies and practices
- Polyomavirus and related diseases
- Potassium and Related Disorders
- Immunodeficiency and Autoimmune Disorders
- Adolescent and Pediatric Healthcare
- Health Systems, Economic Evaluations, Quality of Life
Vifor Pharma (Switzerland)
2022
Janssen (Belgium)
2020
It has remained unclear whether there are clinically meaningful differences between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing the impossibility including large unselected patient populations in randomized clinical trials, as well residual confounding from selection biases observational studies.To study comparative real-world effectiveness for patients schizophrenia.Prospectively gathered nationwide databases were linked risk rehospitalization and...
It has remained controversial if antipsychotic treatment is associated with increased or decreased mortality among patients schizophrenia, and there are any clinically meaningful differences between specific agents routes of administration. We linked prospectively gathered nationwide register-based data during 2006–2013 to study all-cause all aged 16–64 years schizophrenia in Sweden (N = 29,823 total; N 4603 the incident cohort). Multivariate Cox regression models were adjusted for clinical...
TNF inhibitors (TNFis) and IL are effective treatments for PsA. Treatment non-persistence (drug survival, discontinuation) is a measure of effectiveness, tolerability patient satisfaction or preferences in real-world clinical practice. Persistence on these not well understood European PsA populations. The aim this study was to compare time either ustekinumab (IL-12/23 inhibitor) secukinumab (IL-17 reference group adalimumab (TNFi) treatment exposures patients identify risk factors...
The study aimed to (1) compare the risk of health care use, adverse status, and work productivity loss parents patients with schizophrenia multiple sclerosis (MS), rheumatoid arthritis (RA), epilepsy, healthy controls; (2) evaluate such outcome measures while considering disease severity schizophrenia. Based on linkage Swedish registers, at least one parent was included (n = 18215) (information 2006–2013, n 10883). Similarly, parental information linked MS, RA, matched controls, comprising...
Aims. A widespread complication of inflammatory bowel disease (IBD) is iron deficiency anaemia (IDA), which affects quality life (QoL) and associated with frequent hospitalizations. The intravenous therapies, ferric carboxymaltose (FCM), derisomaltose (FD), sucrose (IS), have previously been shown to replenish haemoglobin (Hb) levels more effectively than oral iron. However, they differ in both costs efficacy (response treatment), leading differences acquisition by health-care payers. We...
Human monoclonal antibody ustekinumab is a novel Crohn's disease (CD) treatment blocking pro-inflammatory cytokines interleukin-12 and 23. The study's objective was to assess cost-effectiveness of in moderate severely active CD Sweden.A model with an induction phase decision-tree structure maintenance Markov cohort constructed. represented by five health-states: remission, mild, moderate-severe, surgery death. Ustekinumab compared adalimumab patients who had failed conventional care, some...
Abstract This study aimed to identify if antipsychotic exposure in offspring is associated with psychiatric and non-psychiatric healthcare service use work disability of their parents. Swedish population-based cohort was based on data comprising 10,883 individuals schizophrenia, who had at least one identifiable parent the nationwide registers, parents (N = 18,215). The register-based follow-up during 2006–2013 considered level persistence offspring, further categorized into first (FG)...
Background: Psoriatic arthritis (PsA) is a chronic, heterogeneous, immune-mediated seronegative characterized by joint inflammation in people with skin psoriasis (PsO). In recent years several effective biologic treatments such as tumour necrosis factor inhibitors (TNFi), interleukin (IL) 12 and 23 (IL-12/23i), IL 17 (IL-17i) have been introduced for PsA. Discontinuation (non-persistence) of therapy usually consequence lack effect intolerability. Objectives: Compare time to discontinuation...